![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » COLUMBIA TO STUDY PROCHIEVE FOR PREVENTING PRETERM BIRTH
COLUMBIA TO STUDY PROCHIEVE FOR PREVENTING PRETERM BIRTH
August 4, 2006
Columbia Laboratories has completed enrollment in its placebo-controlled Phase III study of Prochieve 8 percent for the prevention of preterm birth. The prevention of preterm birth would be a new indication for Prochieve, which is currently approved and commercially available to treat infertility and secondary amenorrhea.
This large-scale global trial involves more than 600 patients at more than 60 centers throughout the U.S., Europe, South America, Asia and South Africa. It is designed to assess the ability of Prochieve to safely, effectively and tolerably prevent preterm birth in pregnant women who are predisposed to this problem.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
21Oct